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ABSTRACT 
 
 
Bile Acid Induced Diarrhoea 
 
Pathophysiological and Clinical Aspects 
 
Antal Bajor  
Department of Internal Medicine  
Institute of Medicine at Sahlgrenska Academy University of Gothenburg Sweden 
 
A common cause for referral to gastroenterologists is chronic watery diarrhoea. Approximately 40% 
of these patients have idiopathic bile acid malabsorption (BAM)  a condition with unknown 
aetiology. The 75SeHCAT test, which correlates inversely with faecal excretion and hepatic synthesis 
of bile acids, is used to diagnose BAM.  
The aims of the thesis were to study different mechanisms behind BAM. We investigated the stability 
of the 75SeHCAT test in diarrhoea patients having done the test twice, and in healthy controls. The 
75SeHCAT values were stable over time, suggesting that in clinical practice there is no indication for a 
second test. There was also a strong negative correlation between the 75SeHCAT retention and the 
plasma marker for hepatic bile acid synthesis C4 both in diarrhoea and in controls. 
Impaired ileal absorption of bile acids may be secondary to a defective ileal reabsorbtion system. We 
assessed bile acid uptake in ileal biopsies from diarrhoea patients - both with normal and abnormal 
75SeHCAT test- and compared with the bile acid uptake in ileal biopsies from patients with normal 
bowel habits. Our data suggest that BAM is not caused by impaired bile acid uptake in the ileum.  
We also tested whether BAM is associated with increased active small intestinal chloride secretion as 
estimated from small intestinal potential difference (PD) measurements. We recorded PD during 
manometry in patients with abnormal 75SeHCAT test and compared the values with PD recording 
values in healthy controls. There was a higher PD in the fasting state in the BAM group and there was 
also a negative correlation between the 75SeHCAT test values and the estimated chloride secretion. 
It is known that budosenide has effect on symptoms of diarrhoea both in Crohns disease and in 
collagenous colitis. We investigated whether the improvement in symptoms in collagenous colitis is 
associated with an enhancement of bile acid uptake and/or changes in bile acid synthesis. After 8 
weeks of budesonide treatment the 75SeHCAT values increased significantly, synthesis rate decreased 
and the diarrhoea symptoms improved. 
 
Conclusions: The 75SeHCAT test is stable over a long period of time. C4, the plasma marker for bile 
acid synthesis, may be used in clinical practice instead of the 75SeHCAT test. BAM does not seem to 
be caused by impaired absorption of bile acids in the ileum. A possible mechanism is increased small 
intestinal fluid secretion and motility, which in turn overrides the absorptive capacity of the colonic 
mucosa and leads to diarrhoea. The positive symptomatic effects of budesonide in collagenous colitis 
may in part be mediated by increased ileal absorption and lower colonic concentrations of bile acids. 
 
Keywords: Diarrhoea, bile acid transport, bile acid synthesis, 75SeHCAT reproducibility, C4, 
budesonide, collagenous colitis, in vitro, malabsorption, ASBT, intestinal secretion, potential 
difference, manometry. 
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1. INTRODUCTION 
 
 
Chronic diarrhoea is disabling and it is a frequent cause for referral to gastroenterologists. 
The diagnostic workup in this condition, as recommended by the American 
Gastroenterological Association, is aimed to exclude organic, infectious or metabolic 
disorders. It consists of careful history, physical examination, hematology, chemistry and 
stool tests, gastrointestinal endoscopy with biopsies and in some cases ultrasonography 
and radiologic tests [1]. However, this algorithm does not include any objective 
investigation to diagnose idiopathic bile acid malabsorption, a frequent cause of chronic 
diarrhoea [2-4]. This illustrates the controversy about the existence of this condition, - 
some authors recognize it as a disease entity, other authors consider it as part of the 
irritable bowel syndrome or functional diarrhoea [5]. 
 
 
 
1.1 Historical aspects - three types of bile acid malabsorption  
 
There was experimental evidence already in the sixties that the absorption of bile acids 
occurs against a concentration gradient in the ileum but not in the jejunum. These animal 
studies postulated the presence of an active transport mechanism [6], and led to the 
conclusion that the diarrhoea following ileal resection is secondary to bile acid 
malabsorption [7]. 
 
Further evidence arrived when patients with ileal resection and diarrhoea were treated 
with cholestyramine, a bile acid binder, and those with a resection < 100 cm improved. 
However, patients with resections > 100 cm and a significant steatorrhoea did not respond 
to resins, probably because the bile acid pool was diminished and decreased further by 
cholestyramine treatment. The bile acid malabsorption was demonstrated by intravenous 
injection of sodium- taurocholate14C: more than 50% of the activity was excreted in the 
faeces in 24 hours– normally < 20% should be excreted [8].  
 
Furthermore, patients with non-operated Crohn’s disease with involvement of the terminal 
ileum also frequently have bile acid malabsorption, demonstrated by increased bile acid 
turnover rate as compared to “normals”[9]. Some other injuries to the terminal ileum may 
also cause bile acid malabsorption such as radiation therapy for gynaecological cancer 
[10]. 
 
In conclusion, ileal resection and/or ileal inflammation or radiation injury leads to bile 
acid malabsorption. The above mentioned disease entities with pathologically or 
anatomically defined ileopathy are generally described as bile acid malabsorption type I 
[11 12]. 
 
 2
With the introduction of the 75SeHCAT test it became possible to assess the bile acid 
turnover rate in different diarrhoea conditions [13]. 
Patients with bile acid malabsorption type 1 had accelerated bile acid turnover rate, i.e. < 
10% of the orally administrated bile acid analogue - 75SeHCAT- is left after seven days in 
the enterohepatic circulation [14]. 
 
In the clinical situation we often investigate patients with morphologically intact digestive 
system, where the only abnormality is a reduced 75SeHCAT retention. This condition is 
classified as bile acid malabsorption type II or idiopathic bile acid malabsorption 
(IBAM) and it was believed to be a rare condition previously. However, several studies 
demonstrated that bile acid malabsorption is present in at least 30% of diarrhoea cases 
with otherwise unexplained aetiology [2-4]. 
 
When bile acid malabsorption is associated with other diseases it is classified as type 
III, e.g. post-cholecystectomy [15], familial amyloidosis with polyneuropathy [16], 
collagenous colitis [17], after surgery for peptic ulcer [18], cystic fibrosis with pancreatic 
insufficiency [19-21] and myotonic dystrophy [22]. 
 
  
 
1.2 General description of bile acid synthesis and turnover 
 
The exact aetiology of IBAM is unclear, but before discussing different explanatory 
models, we will briefly summarize current knowledge about the very complex systems for 
bile acid synthesis and reuptake. This system consists of six compartments: 1-liver, 2-
biliary tree, 3-duodenum-small bowel, 4-terminal ileum 5-vena portae and 6-colon 
(Figure 1). For the sake of clarity, each system will first be described separately.  
 
Bile acids are synthesized and conjugated in the liver (compartment 1), excreted through 
the biliary tree (compartment 2), into the small intestine (compartment 3), where bile 
acids participate in solubilization and absorption of dietary lipids. 
 
After their mission in digestion is accomplished, bile acids are reclaimed in the terminal 
ileum (compartment 4) by an active transport mechanism. From the terminal ileum bile 
acids are transported via the portal vein (compartment 5) back to the liver, where they 
enter the hepatocytes finishing the circle of enterohepatic circulation [23], see Fig. 1 on 
next page. 
 
There is only a minimal spill-over of bile acids from the small intestine into the colon 
(compartment 6). By measuring the faecal bile acid output it is estimated that almost 95% 
of the bile acids are reabsorbed per day in the terminal ileum. Bile acid concentrations in 
various tissues illustrate the enormous concentration differences between different 
compartments, see Table1 [23]. 
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5-vena portae
1-liver
4-terminal ileum
6-colon
3-small bowel2-biliary tree
= passive absorption
= active transport
 
Figure 1. Overview of different compartments of the enterohepatic circulation. 
 
 
 
  Table 1.  Concentrations of bile acids in various tissues. 
 
Portal blood  20-50 μmol/L  
 
Plasma fasting < 5 μmol/L  
 
Plasma postprandial Because first pass extraction is constant, 
concentration rises several folds  
Canaliculus and biliary ductulus 20-50 mmol/L  
 
Gallbladder 300 mmol/L in some species  
 
Small intestine 10 mmol/L  
 
Caecum 1 mmol/L  
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1.2.1 Bile acid pool 
 
The bile acid pool is the total amount of bile acids present in the enterohepatic circulation. 
Duane et al determined the bile acid pool with two different methods in 26 volunteers 
with “no evidence of hepatobiliary or other abnormality”, age between 9-34 years. The 
median value of the pool size was 2.7 g (25th to 75th percentile 2.5 to 3.1 g) [24]. 
 
Other investigators have estimated the bile acid pool size to approximately 3 grams in 
healthy humans. In celiac disease there is an enlarged pool of 9 grams and in patients after 
cholecystectomy the pool size may be somewhat reduced, but a study after 5 and 8 years 
in 12 female patients did not find any alteration of the pool size [25-27].  
 
The composition of the bile acid pool is 50 % cholic acid, 30 % chenodeoxycholic acid, 
20% deoxycholic acid and trace amounts of other bile acids [27]. In secondary bile acid 
malabsorption, after ileal resection the bile acid pool is reduced only if the liver cannot 
compensate for the faecal losses. This occurs if the length of the resected ileum is greater 
then 1 m [23]. 
 
 
1.2.2 Bile acid chemistry  
 
Bile acids are poorly metabolized, stable and indigestible molecules, perfectly “designed” 
to fulfil the role of solubilization and absorption of lipids in the gut. However, their 
function is considerably more sophisticated than only being “soaps”- owing to their 
chemical stability bile acids may also act as signalling molecules. 
 
They have a very stable steroid ring core and a side chain. The steroid core or nucleus 
may have hydroxyl groups in different positions, which alter the solubility and 
biochemical properties of the compound. According to the number of hydroxyl groups 
there are mono-, di- and trihydroxy bile acids.  
 
If an amino acid is attached to the side chain the bile acid is conjugated. Before this 
attachment occurs bile acids are called unconjugated. In humans most of the bile acids are 
conjugated to glycin and a smaller amount to taurine [23]. 
 
 
The general structure of the core, the numbering of the carbon atoms and the hydroxyl 
groups in different position are shown in Fig. 2. 
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Figure 2. Bile acid chemistry: CDCA = chenodeoxycholic acid, CA = cholic  
  acid, DCA = deoxycholic acid, LCA = lithocholic acid and  
  UDCA = ursodeoxycholic acid. 
 
 
 
One of the tasks of the liver is to transform cholesterol, a hydrophobic, insoluble 
compound into hydrophilic bile acid molecules by hydroxylation and conjugation. The 
end products of the liver reactions are the primary bile acids, namely chenodeoxycholic- 
and cholic acid. In the intestine, bacteria counteract the attempts of the liver to keep bile 
acids in water solution, by modifying the side chain through deconjugation and altering 
the nucleus through dehydroxylation. By these reactions the secondary bile acids are 
formed, namely deoxycholic-, lithocolic- and ursodeoxycholic acid (the last one only in 
trace amounts). 
 
The bile acids are planar molecules with two “faces”. The hydroxyl groups are present 
only at one face of the molecule, making it hydrophilic. The other face lacks hydroxyl 
groups and therefore is hydrophobic. When several bile acid molecules are present the 
hydrophobic faces tend to aggregate to each other and the hydrophilic faces orientate 
toward the water molecules of a solution. If the aqueous concentration of bile acids 
reaches a critical value they form so called micelles which are small polymolecular 
aggregates which play a key role in lipid absorption [23].  
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1.3 Liver and the systems for bile acid synthesis 
 Compartment 1 
 
 
1.3.1 Bile acid synthesis 
 
There are at least two biosynthetic pathways for bile acid synthesis [28] involving more 
than 12 enzymatic reactions. The classic or neutral pathway is much more important in 
healthy humans, since it accounts for at least 80% of bile acid synthesis, and it is also the 
one involved in feedback regulation [29].The end product of the classical pathway is cholic 
and chenodeoxycholic acid, in roughly equal amounts. The end product of the alternative 
pathway is mainly chenodeoxycholic acid in humans [30]. 
 
The classical pathway begins with conversion of cholesterol to 7α-hydroxycholesterol by 
CYP7A1, cholesterol 7α-hydroxylase, (gene symbol CYP7A1), which is the rate limiting 
enzyme [31]. The second particularly interesting step is the synthesis of the intermediate 
7α-hydroxy-4-cholesten-3 one (C4) which can be measured in peripheral blood and has 
been shown to mirror the bile acid synthesis.  
 
These studies were performed in patients undergoing cholecystectomy for gallstone 
disease with liver biopsies taken during surgery. Some of the patients were pre-treated 
with cholestyramine, a bile acid sequestrant, and others were treated with bile acids to 
alter the feed-back inhibition of the enzyme. There was a strong correlation between the 
plasma concentration of C4 and the activity of the enzyme cholesterol 7α-hydroxylase 
(r=0.9, p<0.0001) [32 33].  
 
In a previous study with similar design, the activity of CYP7A1 was compared between 
patients treated with cholestyramine, chenodeoxycholic acid and untreated controls. In the 
liver biopsies, the enzyme activity was increased 5-fold in the cholestyramine group 
compared to untreated patients. On the other hand, the chenodeoxycholic acid treated 
group had an almost 6-fold lower enzyme activity compared to the untreated controls, 
suggesting that bile acids returning to the hepatocyte might have a strong regulatory 
influence on their own synthesis [34]. 
 
In a study by Bertolotti et al there was also a rather good correlation between hepatic m-
RNA levels for gene expression of CYP7A1 and serum concentrations of 7α-hydroxy-4-
cholesten-3-one in 21 patients undergoing liver biopsy r=0.5, p<0.05 [35]. These patients 
were not treated with drugs interfering with bile acid metabolism. 
 
The bile acid synthesis has been elucidated in different rodent models but there are 
substantial species differences. Humans have two peaks of bile acid synthesis during the 
day, one at 1 PM and the other at 10 PM. In rodents, there is only one peak during the 
night. This diurnal variation is independent of food intake [36]. 
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The regulation of CYP7A1 is very complex and closely related to lipid metabolism. 
Peroxisome proliferator-activated receptor α (PPARα), down-regulates the transcription 
of CYP7A1. The ligands – activators- for PPARα are fatty acids, eicosanoids and drugs 
like fibrates [30]. It has been shown that bezafibrate, a drug used to treat 
hypertriglyceridemia reduces cholesterol 7α-hydroxylase activity in patients with 
gallstone disease [37]. 
 
Hepatocyte nuclear factor 4 (HNF-4), a nuclear receptor, exerts an important stimulation 
of CYP7A1 transcription, by interaction with the transcriptional complex at the promoter 
level, in part independently of the FXR and SHP- cascade (see in section 1.3.3). 
 
 
1.3.2 Feed-back regulation of hepatic bile acid synthesis 
 
When the enterohepatic circulation is disrupted, either surgically, as in biliary diversion 
and ileal resection, or pharmacologically, as in treatment with bile acid sequestrants, the 
hepatic bile acid synthesis is increased [38]. Most of these studies on biliary diversion or 
ileal resection were done during 1960-1970. 
 
Partial ileal bypass surgery was performed in the POSCH trial (Program on the Surgical 
Control of the Hyperlipidemias), when between 1975 and 1983, 838 patients were 
randomized: 417 to the diet control group and 421 to the diet plus partial ileal bypass 
intervention group. The operation involved bypass of either the distal 200 cm or the distal 
one third of the small intestine, whichever length is greater, with restoration of bowel 
continuity by an end-to-side ileocecostomy [39]. In this study the lipid lowering effect is 
partially due to bile acid malabsorption and a compensatory increase of bile acid 
synthesis.  
 
In a similar way the enterohepatic circulation is disrupted when negatively charged bile 
acids bind to resins in the intestinal lumen and are not reabsorbed. In this situation, bile 
acids are lost in stools instead of returning back to the hepatocyte. The disruption of the 
feed-back loop leads to enhanced bile acid synthesis [40].  
 
 
1.3.3 The Farnesoid X receptor and bile acid synthesis 
 
The highly regulated bile acid homeostasis requires intracellular bile acid sensors. The 
most well characterized sensor is the Farnesoid X receptor – FXR or NRH1H4, which has 
the typical structure of nuclear receptors, with a DNA binding domain and a ligand-
binding domain. 
 
It was first shown in 1999 that the natural and most active ligand of FXR is the primary 
bile acid chenodeoxycholic acid but also secondary bile acids, such as lithocholic acid and 
deoxycholic acid have some affinity to the receptor while ursodeoxycholic acid and cholic 
acid have not [41 42]. The affinity of FXR binding to bile acids is in the micromolar range, 
i.e. approximately 1000 times less than that of the binding of steroid hormones to steroid 
receptors (which is in the nanomolar range) [43]. 
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FXR is present in liver, small intestine, colon, kidney and adrenal cortex and it is 
important not only for bile acid synthesis, but also for lipid and glucose metabolism [44]. 
When bile acids return to the liver via the enterohepatic circulation, they activate a 
heterodimeric nuclear receptor RXR- FXR by binding to it. This activation then induces 
the transcription of the nuclear receptor factor short heterodimer partner (SHP) which in 
turn indirectly blocks the transcription of CYP7A1 leading to reduced bile acid synthesis 
[45]. In other words, the interaction of hydrophobic bile acids with farnesoid X receptor 
(FXR), identified as the bile acid receptor, triggers overexpression of the co-repressor 
short heterodimer partner (SHP) [35]. 
 
The mechanism of this indirect blockade is through the involvement of the liver receptor 
homolog-1, LRH-1 or FTF, also called CYP7A1 promoter binding factor (CPF). SHP 
interacts with CPF, prevents its binding to CYP7A1 promoter and consequently the 
transcription is not initiated [45]. 
 
There is an indirect pathway of CYP7A1 blockade, by the interaction of bile acids with 
Kupffer cells resulting in synthesis of cytokines like TNF-α and interleukin-1β. These 
cytokines activate protein kinase C, which in turn activates c-Jun N-terminal kinase 
leading to decreased transcription of CYP7A1 [45]. 
 
FXR also protects the hepatocyte from high intracellular bile acid concentrations by 
suppressing the expression of NTCP gene (Na+ taurocholate cotransporting polypeptide). 
NTCP is responsible for the bile acid influx from the portal venous system to the 
hepatocyte [46]. (For more details see section 1.8, page 13. 
  
 
 
1.4 Bile acid transport through the biliary tree 
 Compartment 2 
 
From the basolateral surface of the hepatocyte, bile acids are transported by intracellular 
trafficking through the cytoplasm to the canalicular membrane. There are several putative 
transport proteins like liver fatty acid binding protein (L-FABP), glutathione S-transferase 
and 3α-hydroxysteroid dehydrogenase (3α-HSD), the latter being the most important one 
in the rat. These proteins are under the control of FXR. In humans these intracellular bile 
acid binding proteins are not well characterized [46]. 
 
Bile acids are excreted via the canalicular membrane into the bile. This process is energy 
consuming because the bile acid concentration gradient between the portal blood and bile 
canaliculus may be as high as 1000-fold [47]. To secure the energy supply of canalicular 
bile acid excretion, the transporter function is dependent on ATP hydrolysis. The two 
most important transporters are the Bile Salt Export Pump (BSEP) and the Multidrug 
Resistance Protein (MRP2). BSEP is regulated in a positive feed-forward fashion by bile 
acids through FXR [46]. 
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1.5 Bile acid uptake in the proximal small intestine 
Compartment 3 
 
Bile acid uptake in the proximal small intestine is mainly passive, but there is also an 
active bile acid uptake, which involves a sodium independent transporter, organic anion 
transporter subtype 3 (oatp-3). The function of this transporter is not well understood in 
humans, but the gene encoding this protein has been mapped both in humans and in rat 
[48]. 
 
FXR is involved also in the cross talk between the small intestine and the liver. When bile 
acids enter small bowel enterocytes, FXR stimulates the transcription of the signalling 
molecule fibroblast growth factor (FGF) 15 in mice, or its human ortologue FGF19 in 
man. FGF 19 returns to the liver by the portal vein and here suppresses bile acid synthesis 
[49]. 
 
The proximal small intestine will harbour relatively large amounts of bile acids involved 
in the fat absorption process. We will now discuss briefly how intestinal bile acid 
handling is linked to intestinal motility and secretion. 
 
 
1.5.1 The motor and secretory activity of the small intestine in the fasting 
state 
 
With the introduction of small bowel manometry, it was shown that in virtually all 
mammals as well as in humans, there is a cyclic motor activity during the fasting state 
[50]. This cycle, called the migrating motor complex (MMC) is divided into three phases 
by three different motility patterns. Phase I has no motor activity, in phase II there is an 
irregular and low frequency activity and in phase III the contractions are regular, with 
different frequencies in different parts of the intestine, i.e. three cycles/minute in the 
antrum, 10-12 in the duodenum and 7-9 in the distal ileum [51]. 
 
Not only the frequencies but the propagation velocities differ in different parts of the 
intestine, the speed in the duodenum being approximately 10 cm/minute, in the jejunum 
7-8 cm/minute and in the ileum 1 cm/minute [52]. Not all phase III-s propagate throughout 
the small intestine; in the referred study of Kellow et al the majority of the complexes 
“died out” and only approximately 10% reached the ileocecal valve [52].  
 
The duration of an MMC cycle is measured as the time between the end of two 
consecutive phase III periods and is approximately 100 min. In a study of Björnsson et al, 
the median value was 108.5 minutes [53]. There is a huge inter- and intra-individual 
variation between the duration of the MMC cycles [54]. 
 
The function of the MMC cycle is probably to clean the small intestine from its debris and 
to prevent bacterial overgrowth. Bacterial overgrowth is associated with motility 
disturbances like the absence of the MMC complexes [50]. Posserud et al found that 86% 
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of IBS patients with small intestinal bacterial overgrowth diagnosed with culture of 
jejunal aspirates had signs of enteric dysmotility in contrast to 39% of the IBS patients 
with negative jejunal cultures [55]. 
 
During phase III, the small intestine becomes a net secretory organ and the MMC can be 
seen as the motor component of a complex secretomotor rinsing programme [56]. There is 
a net chloride secretion during phase III which occurs against an electrochemical gradient, 
resulting in a potential difference between the gut lumen and the extracellular 
compartment with more negative lumen [57]. 
 
The use of phase III activated PD as a marker for electrogenic chloride secretion is based 
on the finding that phase III motor activity is not accompanied by any change in PD in 
patients with cystic fibrosis, a congenital disorder in which CFTR, the chloride secreting 
channel, does not open when activated [58]. 
 
 
1.5.2 Handling of bile acids in biliary system during the fed state 
 
Bile acids secreted by the hepatocytes are excreted through the biliary system. Bile is 
concentrated and stored in the gall bladder and is released into the duodenum mainly in 
association with meals. The most important control mechanism for bile release into the 
duodenum is CCK release from chemosensitive enteroendocrine cells in the duodenal 
epithelium. CCK is released in response to duodenal lipids. CCK contracts the gall 
bladder and relaxes the sphincter of Oddi [59 60].  
 
Smaller amounts of bile are also released intermittently in the fasting state, as part of the 
MMC rhythm. In late phase II, the gallbladder empties partially, and the sphincter of Oddi 
relaxes. Bile release occurs during a period with antegrade peristalsis in the duodenum 
(late phase II and early phase III). In late phase III, sphincter of Oddi closes, and when 
retroperistalsis occurs in late phase III, there is normally no bile present in the duodenum 
[56]. The physiological role of this very complex system is unknown. 
 
 
1.5.3 The effect of bile acids on motility 
 
There is a more rapid small bowel transit in idiopathic bile acid malabsorption compared 
with healthy controls, when transit time is measured with radio-opaque markers [61]. In 
contrast, when glycochenodeoxycholic acid was infused in the last 40 cm-s of the ileum, 
the motility of the jejunum and ileum was inhibited resulting in delayed transit [62]. 
 
In patients with “irritable colon”, when the terminal ileum was infused with bile acids, 
there was an exaggerated PD reaction [63]. The effects of physiological amounts of bile 
acids on small intestinal motility are not well characterized.  
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1.6 Bile acid uptake in the terminal ileum 
 Compartment 4 
 
 
1.6.1 Bile acid uptake 
 
Daily bile acid losses are approximately 0,5 g through the faeces in humans with normal 
bowel habits [64]. The release of bile acids from the liver into the intestine varies between 
15 to 25 g/day [65]. This means that bile acids are highly absorbed in the intestine and 
indicates the existence of active transport systems. 
 
The ileal bile acid absorption efficiency during a single enterohepatic cycle was 
investigated in six healthy subjects by Galatola et al. They used an occluding balloon 
distal to ampulla of Vater, infused both 75SeHCAT and 14C labelled taurocholate, and 
measured the faecal excretion of these markers after intestinal washout. In a single cycle, 
there was very little variation of bile acid uptake between individuals, the mean value of 
absorption being 96%, (range 95%-97%). There was however a substantial variability 
after 24 hours, suggesting that the number of enterohepatic cycling per day may differ 
widely [66].  
 
The quantitatively most important transport protein is the apical sodium dependent bile 
acid transporter ASBT which is abundant in the distal 100 cm of the ileum [67]. The 
importance of this protein is emphasized by the fact that it exists in all vertebrates studied 
[65]. Interestingly, ASBT knockout mice are physically indistinguishable from wild type 
mice [68]. The gene SLC10A2 coding for ASBT is cloned in humans and a rare mutation 
of this gene leading to interruption of the enterohepatic bile acid circulation has been 
described [69].  
 
The regulation of ASBT is species dependent. In human Caco-2 cell cultures, ASBT is 
positively regulated by retinoic acid and bile acids induce a negative feedback regulation 
of ASBT via an FXR-mediated, SHP-dependent effect [70]. Inflammatory cytokines 
inhibit ASBT expression in Caco-2 cell cultures by the so called c-Jun N-trerminal kinase 
(JNK) dependent pathway [71]. 
 
ASBT is also up-regulated by peroxisome proliferator-activated receptor α (PPARα), 
which is a regulator of fatty acid catabolism and also of hepatic bile acid synthesis [72]. 
PPARα is activated by fatty acids, eicosanoids and drugs like fibrates. 
 
Cholesterol feeding down-regulates ASBT in mice and the presence of cholesterol in 
media of human Caco-2 cell cultures has similar inhibitory effect. The mechanism is not 
fully understood, but a new pathway involving a partnership between SREBP-2 and HNF-
1α may be responsible [73]. 
 
Liver receptor homolog-1 (LRH-1; also called FTF, -fetoprotein transcription factor in 
other species) is involved in the down-regulation of ASBT in some species e.g. the rabbit. 
The group of Guorang Xu identified a FTF functional binding element in the rabbit ASBT 
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promoter. They concluded that “a functional FTF binding site as well as functioning FXR 
are required for the negative feedback regulation of rabbit ASBT by bile acids. Only 
FXR-activating ligands can down-regulate rabbit ASBT expression via the regulatory 
cascade FXR-SHP-FTF” [74]. 
 
However, there are only a few in vivo studies about ASBT regulation in humans with one 
study showing down-regulation of ASBT in ileal Crohn’s disease and up-regulation 
during glucocorticoid treatment [75]. 
 
 
1.6.2 Intracellular bile acid transport in the small intestine 
 
High concentration of bile acids can cause disruption of membranes due to their detergent 
properties. There are therefore mechanisms to monitor intracellular bile acid 
concentrations like with FXR, and also proteins having the task to bind bile acids and 
shuttle them through the cytoplasm.  
 
The intestinal or ileal bile acid binding protein (IBABP), also known as ileal lipid 
binding protein (ILBP), with the gene symbol FABP6, is such a shuttle transporting bile 
acids from the apical to the basolateral surface of the enterocyte. IBABP also binds to 
cholesterol and fatty acids. It is up-regulated by bile acids through FXR, i.e. bile acids 
entering the ileal enterocyte increase the amount of IBABP [76]. The function and 
regulation of IBABP is not entirely known, because FXR knock-out mice have very low 
IBABP expression but increased intestinal bile acid absorbtion [77]. 
 
From the basolateral membrane bile acids are secreted to the portal venous circulation 
probably by a heterodimeric transporter composed of two subunits Ostα/ Ostβ [78 79]. 
 
 
 
1.7 Bile acid transport from the intestine to the liver  
Compartment 5 
 
From the enterocyte, bile acids are transported tightly bound to albumin in the portal 
circulation. In plasma, besides albumin binding bile acids are also bound to lipoproteins, 
mainly HDL [47]. From the portal vein, bile acid are very efficiently extracted by the liver, 
between 70% and 95% are thus cleared by the first passage. The affinity is higher for 
trihydroxy than for dihidroxy bile acids, and the uptake system is seemingly unsaturable 
under physiological conditions. 
 
To illustrate the efficiency of the system, Angelin et al found that the maximum 
postprandial portal venous bile acid concentration averaged 43.04+/-6.12 μmol/liter, and 
the corresponding concentration in peripheral serum was 5.22+/-0.74 μmol/liter [80]. 
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1.8 Bile acid transport into the hepatocyte – back to  
 Compartment 1 
 
In the hepatocyte the main transport protein for bile acid uptake is Na+ taurocholate 
cotransporting polypeptide (NTCP, SLC10A1). It has high affinity to taurocholate, (Km 
~ 6 μmol/liter) but also transports unconjugated bile acids. Structurally it is very similar to 
the intestinal ASBT protein and is localized at the basolateral hepatocyte membrane. 
 
The expression of NTCP is altered in pregnancy, cholestatic alcoholic hepatitis and 
advanced primary biliary cirrhosis where the NTCP gene expression is suppressed by 
elevated concentration of bile acids in order to prevent their entry to the hepatocyte. This 
suppression is also mediated through FXR [46].  
 
Inflammation suppresses NTCP expression by the JNK dependent pathway in analogue 
fashion to the down-regulation of ASBT [46]. Like its intestinal counterpart (ASBT), 
NTCP is up-regulated by glucucorticoid treatment [81].  
 
There is also a Na+ independent uptake system in the hepatocyte, namely the organic 
anion transporting polypeptides with 4 different proteins, the most important being 
OATP1B1/SLC01B1 (formerly called OATP-C) with Km for taurocholate between 14-34 
μmol/liter. Of less importance are OATP1A2/SLC01A2 (OATP-A) and 
OATP1B3/SLC01B3 (OATP8) [47]. These transporters are responsible for most of the 
uptake of the unconjugated bile acids [46]. 
  
 
 
1.9 Bile acid transport through the colon - Compartment 6 
 
 
1.9.1 Faecal losses 
 
Even if bile acids have not been absorbed by the active transport system in the distal 
ileum, they can re-enter the enterohepatic circulation by passive diffusion. This passive 
absorption is strongly dependent on colonic pH and also whether bile acids are 
deconjugated and/or dehydroxylated by the colonic flora. Perfusion studies have shown 
that the rate of absorption is highest for chenodeoxycholic -, intermediary for deoxycholic 
- and lowest for cholic acid [82]. 
 
There are only few studies in the literature about bile acid malabsorption and 
quantification of faecal bile acids and even fewer studies about direct measurement of 
faecal bile acids and their relation to the 75SeHCAT test [83-85]. The most accurate method 
for the assessment of faecal bile acid output is gas chromatography-mass spectrometry. In 
the clinical situation, less accurate enzymatic methods are frequently used [64].  
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Porter et al has determined faecal bile acid output in 10 healthy subjects with normal 
bowel habits and in 16 patients with diarrhoea. The median value in normal subjects was 
0.315 g/day (0.2-0.73) and in diarrhoea 1.4 g/day (0.7-3.5). However, these patients had 
severe bile acid malabsorption secondary to systemic amyloidosis (3 patients), ileal 
surgery or radiation enteritis (5 patients). There was also a significant correlation between 
faecal weight and bile acid output [64].  
 
 
1.9.2 Mechanisms of bile acid induced diarrhoea in the colon 
 
The aqueous concentration of total bile acids in human caecum is approximately 0.6 mM 
(mM = μmol bile acid/ ml fluid) [86].  
Colonic water secretion starts when bile acids reach the micellization concentration of 1-2 
mM. However, there are differences between dihydroxy and trihydroxy bile acids, 
because cholic acid does not induce secretion, but chenodeoxycholic- and deoxycholic 
acid does. Deoxycholic acid induces net water secretion at 3 mM contration and 
chenodeoxycholic acid at 5 mM [87]. 
 
In a rat model, colonic secretion of Cl- occurred between the taurodeoxycholate 
concentrations of 0.5-2 mM. With further increase of TDCA concentration, irreversible 
cytotoxic effects were seen [88] . 
Because the solubility of bile acids is pH dependent, high colonic pH perpetuates their 
secretory effects [89]. Increased colonic permeability, mediated by enteric neurons and 
increased colon motility are also diarrhoea-promoting effects of the high luminal 
concentrations of bile acids [90]. 
 
The chemical reactions of deconjugation, dehydroxylation and modification of the side 
chain are carried out by bacteria [91]. The anaerobic bacterial flora in the colon can 
generate 15–20 different bile acid metabolites [92] but degradation of the steroid ring to 
CO2 probably does not occur in the colon. There are also bacteria which do not occur in 
living organisms that are able to completely metabolize cholesterol and also bile acids to 
CO2 [92 93]. 
 
By using colonic epithelial cell cultures it has been shown that the secretory effect of bile 
acids is determined by the steroid ring structure and the length of the side chain. When 
cholic acid is converted to deoxycholic acid by bacterial dehydroxylation, a non-secretory 
bile acid is converted into a secretory one. When chenodeoxycholic acid, a secretory bile 
acid, is dehydroxylated, the result is lithocholic acid, which lacks secretory properties [87]. 
To sum up, the colonic bacterial flora might determine the chemistry of the bile acid pool 
in the large intestine and hence the secretory properties – from constipation to diarrhoea. 
The fact, that bile acid chemistry highly regulates the secretory response in the colon, 
suggests the existence of a bile acid “sensor” or “receptor”.  
 
There are also important inter-individual variations between the caecal bile acid 
composition with at least 90% in deconjugated form. The bile acid pool in the caecum is 
composed of approximately 15% cholic -, 30 % deoxycholic -, 20% chenodeoxycholic -, 
20% lithocholic- and 2% ursodeoxycholic acid. It is also important that up to 25% of bile 
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acids are present in 3β-hydroxy isoform. These 3β-hydroxy bile acids are promptly 
absorbed and are reepiremezed after returning to the liver to α- hydroxy isoform thus 
contributing to the enterohepatic circulation [86]. 
 
The exact mechanism by which bile acids induce diarrhoea is not known. Studies 
performed from the sixties to early eighties have shown that the colon is a net absorbing 
organ even in the presence of severe inflammation. The only inflammatory bowel disease 
where net fluid secretion is reported is collagenous colitis [94]. In this disease the colonic 
crypts are not affected as in contrast to ulcerative colitis or Crohn’s disease. High 
concentrations of bile acids enough to activate fluid secretion are unlikely to occur in the 
physiologic state [86]. 
 
However bile acids might increase rectal sensitivity. In an experiment with 11 healthy 
subjects, rectal infusion of deoxycholic acid at 1 and 3 mmol/l concentrations increased 
the sensitivity of the rectum to distension, and promoted urgency to defecate. Seven 
subjects could not tolerate infusion with 3 mmol/l deoxycholic acid [95].  
In the small intestine, bile acids (e.g. deoxycholic acid) at mM concentrations do induce 
fluid secretion, and this response is at least partially due to activation of enteric neurons 
[96]. 
 16
1.9.3 The composition of the bile acid pool in different conditions of bile acid 
 malabsorption 
 
The data on bile acid pool composition are generally based on small numbers of 
experiments. In the study of Fracchia et al, 13 patients with idiopathic bile acid 
malabsorption have been compared to 23 controls. They found a significant decrease of 
cholic acid expressed as percentage of the bile acid pool, but no alteration of the ratio 
between dihydroxy-to trihydroxy bile acids. They concluded that “the mechanism of 
diarrhoea does not seem to depend on an enrichment of the bile acid pool with dihydroxy 
bile acids” [97]. 
 
In secondary bile acid malabsorption as in Crohns disease, Lapidus et al found a 
significant decrease in the deoxycholic acid fraction and a prominent increase in the 
ursodeoxycholic acid fraction [98]. 
 
 
1.10 Aetiology of bile acid malabsorption type II  
 (idiopathic bile  acid malabsorption) 
 
Rare cases of idiopathic bile acid malabsorption were described as secondary to a 
mutation in the ileal sodium-dependent bile acid transporter gene (SLC10A2) [69]. This is 
a severe condition, with diarrhoea and steatorrhoea present already at birth, weight 
deficiency and impaired lipid absorption. There is also a knockout mouse model of bile 
acid malabsorption with targeted deletion of the slc10a2 gene. Interestingly, these animals 
do not have diarrhoea or weight loss despite a 10 fold increase in faecal bile acid output 
[68]. 
 
In adult onset bile acid malabsorption there was no dysfunctional mutation of the 
(SLC10A2) gene in 13 patients [99] and alternative explanations were suggested as a cause 
of the disease.  
Van Tilburg et al have previously shown an increased uptake of taurocholic acid in 
idiopathic bile acid malabsorption [100]. They constructed brush border membrane vesicles 
from ileal tissue obtained from diarrhoea patients, including those with bile acid 
malabsorption. Furthermore, in a subsequent study they found an expanded bile acid pool 
in these patients. 
 
Their findings indicate that high concentrations of bile acids in the small bowel may 
overload the saturable active uptake, causing the increased spill over of bile acids to the 
colon [101]. This idea is in line with a study in our clinic by Sadik et al who demonstrated 
an accelerated small bowel and distal colonic transit as well higher body mass index 
(BMI) in patients with adult onset bile acid malabsorption [61].  
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1.11 Treatment of bile acid malabsorption 
 
Bile acid binding resins: There are only a few placebo-controlled trials for treatment of 
bile acid malabsorption. One study investigated the effect of enterocoated cholestyramine 
on symptoms of diarrhoea in patients with ileal resection and Crohn’s disease and found 
significant effects [102]. Another study investigated the effect of cholestipol on symptoms 
in critically ill patients starting enteral feeding after prolonged fasting. The authors 
postulated that these patients had a relative luminal excess of bile acids leading to 
choleretic diarrhoea and found beneficial effect of bile acid binders [103]. 
 
There are numerous uncontrolled, open label studies in bile acid malabsorption showing 
beneficial effects of resins [3 8 104]. One potential drawback is the very high 
discontinuation rate of medication. This has been systematically assessed in 363 patients 
when resins were used for cholesterol lowering indication and it was found that only 17% 
was still taking the drug after 4 years [105]. 
 
Cholesevelam is a new bile acid binder with at least four times higher affinity to bile acids 
compared to the older cholestyramine and cholestipol [106 107]. This new drug was tested in 
five patients with bile acid malabsorption and intolerance to cholestyramine showing 
excellent effect on diarrhoea symptoms [108].  
 
There are anecdotic reports about the effect of unspecific chelators such as aluminium 
hydroxide on bile acid malabsorption [109 110]. 
 
Loperamide: Although it is widely used in diarrhoea conditions, there is only one 
placebo-controlled trial, namely in radiation enteritis showing good effect on symptoms 
[111]. 
 
Corticosteroids and budesonide: In Crohn’s disease and in collagenous colitis there is 
clinical evidence for induction of remission both with conventional corticosteroids and 
with budesonide [112 113]. Budesonide is a corticosteroid designed to achieve a topical 
effect in the terminal ileum and proximal colon [114]. 
 
The mechanism behind the often dramatic improvement of the symptoms by budesonide 
treatment is still unknown. In animal models, corticosteroids up-regulate the expression of 
the Apical Sodium Dependent Bile Acid Transporter (ASBT) [115]. 
 
In a study in healthy humans Jung et al have shown that ASBT protein expression 
increased after budesonide treatment. They suggested that induction of ASBT by 
budesonide leading to a reduced bile acid load on the colon could be an important 
mechanism behind the symptomatic improvement in patients with Crohns disease [75]. 
There are no clinical trials with corticosteroids or budesonide in bile acid malabsorption 
type II. 
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Diet and lifestyle: Amelioration of diarrhoea may be achieved with low fat diet, both in 
patients with bile acid malabsorption secondary to radiation enteritis [116] or Crohn’s 
disease [117]. This diet has not been tested systematically in bile acid malabsorption type 
II. 
 
Bile acid replacement therapy: Patients with extensive ileal resection (>100 cm) did not 
respond to cholestyramine treatment in the study of Hofmann et al [8]. It was postulated 
that these patients had diminished bile acid pool and cholestyramine further reduced it, 
accentuating the initial steatorrhea. Replacement therapy with the synthetic bile acid 
cholylsarcosine improved fat absorption and resulted in weight gain in an open label study 
in patients with short bowel syndrome [118] or in a case report [119]. 
 
FXR agonists: Bile acids bind to FXR and indirectly suppress the rate limiting enzyme of 
bile acid synthesis, cholesterol 7α-hydroxylase [45]. There are FXR agonists, which bind 
more potently to FXR than natural bile acids, like 6α-Ethyl-Chenodeoxycholic acid [120] 
and nonsteroid ligands such as GW4064 [121]. 
Theoretically, these compounds reduce bile acid synthesis and consequently could be 
tested in bile acid malabsorption. However, these compounds are primarily designed for 
cholestatic liver diseases, as they also promote bile acid excretion from the hepatocyte. 
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2. AIMS OF THE PRESENT STUDY 
 
 
As mentioned previously, relatively little is known about the causes of idiopathic bile acid 
malabsorption. The treatment of this condition is symptomatic by using bile acid binding 
resins.  
 
The present thesis had the following aims:  
 
To evaluate the diagnostic accuracy and reproducibility of the 75SeHCAT test and whether 
it declines with aging (paper I). 
 
To test the hypothesis that active bile acid uptake in the distal small intestine is reduced in 
bile acid malabsorption (paper II). 
 
To test the hypothesis that patients with bile acid malabsorption have an increased fluid 
secretion in the small intestine - which may result in bypass of normally functioning distal 
absorption systems - (paper III). 
 
To evaluate the role of colonic inflammation (collagenous colitis) in bile acid 
malabsorption and to test whether the improvement in symptoms in collagenous colitis 
during budesonide treatment is associated with an enhancement of bile acid uptake and/or 
changes in bile acid synthesis (paper IV). 
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3. SUBJECTS AND METHODS 
 
 
3.1 Subjects and inclusion criteria 
 
Informed consent was obtained from all participants and the local Ethics Committees and 
the Radiation Protection Committee at the Göteborg University approved the study. 
 
 
Healthy controls (Paper I, III and IV) 
 
Twenty nine healthy subjects with normal bowel habits underwent a 75SeHCAT test in 
1989 [2]. These historical data were used as reference values for the 75SeHCAT test in 
paper IV. Between 2004 and 2006, 19 of the subjects were located and 16 reported that 
they were still healthy with normal bowel habits and they agreed to undergo a second test. 
On this occasion the hepatic synthesis of bile acids was estimated by measure of the 
plasma marker (C4) in 14 subjects. Body mass index (BMI) was registered at both 
occasions (paper I). 
The small intestinal manometry and PD measurement were performed in 18 healthy 
volunteers (paper III). 
  
 
Control patients with normal bowel habits (Paper II) 
 
In the experiment concerning bile acid uptake capacity in ileal biopsies seventeen patients 
with normal bowel habits served as controls. They were recruited during colonoscopy and 
if the macroscopic appearance of the bowel was abnormal, suggesting inflammation or 
malignancy than the patients were not included in the study. 
To investigate the correlation between ileal ASBT concentrations and bile acid uptake, 
multiple biopsies were taken during surgery from five patients operated for continent 
urinary diversion with an ileal reservoir. These patients had normal bowel habit.  
 
 
Diarrhoea patients (Paper I, II and III) 
 
In paper I, the patients were recruited retrospectively. All 75SeHCAT tests performed 
between 1986 and 2001 at the Department of Nuclear Medicine in Skövde Hospital were 
reviewed and patients who had undergone two 75SeHCAT tests were identified. The 
values from the first and second 75SeHCAT tests among the patients with unchanged 
conditions were compared with regard to factors known to interfere with the absorption of 
bile acids. The age at the first investigation, gender, clinical diagnosis and time between 
the two 75SeHCAT tests were registered. 
 
Patients with chronic diarrhoea who were referred to our gastroenterology unit were 
included prospectively in the study in paper II. The symptom duration was at least three 
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months. Those with abnormal macroscopic appearance at colonoscopy, suggesting 
inflammatory bowel disease or malignancy, were excluded. All in all 53 patients with 
macroscopically normal ileum were included and none of them had previous bowel 
surgery. 
 
Regarding the eleven patients from paper III, bile acid malabsorption was defined as a 
combination of diarrhoeal symptoms during at least three months and a subnormal value 
for the 75SeHCAT test (<10% retention at day seven). Celiac disease was excluded by 
serological tests and/or duodenal biopsies, and infectious causes were excluded by routine 
faecal cultures and microscopy. All but one patient had their gall bladder in situ and 
another patient has performed a gastric banding operation previously. One patient had 
ulcerative colitis with endoscopically normal terminal ileum, otherwise none of them had 
inflammatory bowel disease or microscopic colitis. 
  
 
Patients with collagenous colitis (Paper IV) 
 
Patients investigated for chronic diarrhoea who were diagnosed with collagenous colitis 
after a standard clinical work-up or had a previously known collagenous colitis with a 
relapse were included in the study. Conventional criteria for collagenous colitis were used 
-microscopic inflammation including an increased number of intraepithelial lymphocytes, 
inflammatory cells in the lamina propria with mainly mononuclear cells, epithelial 
damage such as flattening and detachment and a subepithelial collagen layer of at least 10 
μm [122-126]. For comparison, previously published 75SeHCAT retention data from 29 
healthy controls were provided as described in the healthy control section. 
 
Methodological comments: The definition of diarrhoea is poorly standardised. When we 
included our patients, one criterion was the reported duration of diarrhoeal symptoms of 
at least 3 months. Not all patients registered their bowel habits, but those referred to the 
75SeHCAT test routinely underwent a symptom registration during the test week. 
 
 
 
3.2 Symptom recording 
 
At the start of the 75SeHCAT test the patients received a questionnaire to record the 
number of bowel movements, stool consistency, the symptoms of abdominal pain, 
distension and flatulence. The scores used were 0, absent; 1, mild; 2, moderate; 3, severe. 
The consistency of faeces was estimated as 1, watery; 2, loose; 3 firm. The arithmetic 
mean of the scores was calculated for each symptom as well as for consistency. See 
questionnaire Fig. 3. 
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VAR VÄNLIG REGISTRERA DINA MAGBESVÄR! 
 
 
Namn: 
 
Personnummer: 
 
Period: 
 
 
BESVÄRSTYP Må Ti Ons Tors Fre Lö Sön 
Buksmärta            (0-3)        
Bulsvullnad          (0-3)        
Riklig gasavgång (0-3)        
 
0 = Inga besvär 
1 = Lätta besvär 
2 = Medelsvåra (stör, men förhindrar ej arbete) 
3 = Svåra besvär (t.ex. arbete avbryts eller sängläge intas 
 
 
 
AVFÖRINGAR Må Ti Ons Tors Fre Lö Sön 
Antal per dygn        
Konsistens        
Nattliga avföringar (X = Ja)        
 
1 = Vattentunn 
2 = Lös (välling, gröt) 
3 = (Formad) 
 
Egna kommentarer (t ex andra magbesvär):         
  
 
 
 
 
Aktuella mediciner:             
 
 
 
Ev. utsatta mediciner och datum:         
  
 
 
 
 
   Figure 3. Questionnaire 
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3.3 The 75SeHCAT test  
(Paper I-IV) 
 
The test was introduced by Thaysen and has been described in previous articles [13].A 
capsule containing 0.3 MBq 75SeHCAT was swallowed in the morning after one night 
fasting. The geometric mean of frontal and posterior measurements with an uncollimated 
gamma camera was calculated. The initial value, representing 100%, was measured 3 
hours after ingestion of the capsule. A repeated measurement was performed after 7 days. 
Retention values less than 10% on day 7 were considered abnormal.  
 
This method was used in paper II, III and IV. In paper III it was used a simplified 
method where measurements were performed using an uncollimated gamma camera 
(Starcam System) with the patient in a supine position and the gamma camera positioned 
at a distance of 60 cm. The basal value (100%) was obtained with a measurement over the 
capsule. A new measurement was taken over the abdomen after seven days. The 
abdominal retention was calculated as a fraction of the basal value. A retention value of > 
10% on day 7 was considered as normal [2]. 
 
All medication with a potential effect on diarrhoea was excluded during the study week, 
i.e. bile acid binding resins, loperamid, codein, etc. 
 
Methodological comments: Gamma ray attenuation could be more pronounced in 
patients with considerable overweight. It has been performed both kind of measurements 
in the Department of Nuclear Medicine at Sahlgrenska University Hospital using so called 
phantom models. These measurements didn’t show substantial differences between the 
results of two methods (personal communication, L. Jacobsson). During a time period 
between 1990 and 2005 it has only been used the simplified 75SeHCAT measurement as 
described in the method section. 
 
Theoretically, the cut off value for abnormal 75SeHCAT test should be the (Mean value of 
29 healthy controls – 1.96 x SD) = (39.1% -1.96 x 17.7) = 4.4%. In our clinics the cut off 
value is considered 10% retention at day seven like in other centres [127]. 
 
However, these values are somewhat arbitrary, as Fernandez-Banares et al has used <11% 
and Wildt et al <15% as abnormal retention [4 128]. The rational behind the 10% cut off 
value is based on the study by Williams et al where eight patients with 75SeHCAT 
retention > 10% but < 15% did not respond to cholestyramine treatment, in contrast to the 
23 patients with 75SeHCAT retention <5% responding to resin therapy [129]. It should be 
emphasized, that in the study of Wildt et al, the best response to treatment was also in the 
patients with idiopathic bile acid malabsorption and/or a retention value of < 5% [128]. 
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3.4 Assay of 7α-hydroxy-4-cholesten-3-one (C4) 
(Paper I, II and IV) 
 
For the estimation of hepatic bile acid synthesis, one ml of blood serum was assayed for 
C4 by high performance liquid chromatography. The blood samples were taken in the 
morning under fasting conditions and were frozen immediately to –80° Celsius. The 
samples were than analyzed at the laboratory of the Department of Endocrinology, 
Karolinska University Hospital, Huddinge as described previously [130]. 
Methodological comments: As plasma C4 relative to total plasma cholesterol is a better 
marker for hepatic bile acid synthesis than the absolute C4 concentration, the ratio of 
C4/chol was also calculated and evaluated, but for simplicity the plasma C4 concentration 
was applied [131]. There were no differences between the results when the two different 
markers for hepatic bile acid synthesis were used. 
 
 
 
3.5 Assay of bile acid uptake 
(Paper II) 
 
Technical procedure 
 
Twelve biopsy specimens were taken from the ileum approximately 10 cm-s proximal 
from the ileocecal valve for the bile acid uptake assessment. Patients were excluded if 
biopsy specimens could not be obtained from the ileum.  
 
The biopsies were incubated for 45 minutes in Krebs solutions at 37° C containing three 
different concentrations of 14C labelled taurocholate, a β particle emitting compound. The 
taurocholate concentrations were 100, 200 and 500 μmoles and four biopsies were used 
for each concentration.  
 
After the incubation the biopsy specimens were freeze-dried, weighed and than dissolved 
in Soluene®-350 in order to mix with a scintillation cocktail. The absorbed radioactivity 
was measured using a liquid scintillation β-counter. 
 
Estimation of taurocholate uptake 
 
For each series the measured radioactivity (the mean value of the four measurements) was 
plotted on the Y axis and the taurocholate concentrations in the incubation media were 
plotted on the X axis (100, 200 and 500 μmoles on the X axis). The taurocholate uptake 
follows a straight line at concentrations between 100 and 500 μmoles in the medium [67]. 
This indicates that the active uptake is saturated above the concentration of 100 μmoles.  
 
The three points of the diagram were connected to a line which was extended to 0 μmoles 
concentration – a point where the extended line meets the y axis. The maximal ability for 
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active bile acid uptake of the mucosal specimens was calculated from the intercept of this 
extended straight line with the y axis, at which point the concentration of taurocholate is 
zero and there is no passive absorption.  
 
Methodological comments: This method was validated previously, when different 
tissues were tested [67]. According to methodological study, the estimated 14C 
taurocholate uptake was high in the terminal ileum and approximately 75% lower in the 
ileum 100 cm proximally from the ileocaecal valve, very low in the duodenum, and in the 
right colon. The uptake capacity was measured using devitalized tissue from the terminal 
ileum and also using an inhibitor of the transporter protein (ASBT) showing very low 
uptake. 
 
The incubation time of 45 min is based on the study of Hosie et al who has reported a 
linear uptake within the interval of 5 to 45 minutes [132]. 
 
 
 
3.6 Western blot analysis to quantify the ASBT protein  
 
In five patients who were operated for continent urinary diversion with an ileal reservoir, 
multiple biopsies were taken during surgery, both for the bile acid uptake assay and for 
the western blot analysis. The method is described in detail in paper II. 
 
Methodological comments: The depth of the biopsy may affect the amount of the ASBT 
protein since it includes non epithelial components in a variable manner. To circumvent 
this potential artefact the ASBT concentration was corrected to villin concentration of the 
very same biopsies. Villin is a marker for epithelial cells displaying a brush border and it 
is present in epithelial cells of the gastrointestinal, urinary and respiratory tract. Its 
synthesis increases during the maturation of the enterocyte, which takes place when the 
enterocytes migrate from crypts to the tip of the villus [133]. 
Since the Western-blot analysis is only semi-quantitative, ranks have been used instead of 
absolute values. 
 
 
 
3.7 Small intestinal manometry and mucosal potential difference  
 
The experimental setup is described in more detail in paper III and in previous articles [56 
134]. Briefly, in the morning after an overnight fast, the subjects were intubated 
transnasally with a multilumen polyvinyl tube containing eight separate channels, six of 
which were used in the experiment. The tip of the tube was placed in the proximal 
jejunum, under fluoroscopic guidance. 
 
The pressure was recorded in the proximal jejunum channel (1), duodenojejunal junction 
(2), at three channels with 1.5 cm distance in between in the mid duodenum in the papilla 
region (3-5), and one channel in the antrum (6). Each pressure-recording channel (except 
those used for recording of transmural PD) was perfused with water at a rate of 30 ml/hr. 
 26
The low-compliance water perfused system is considered the standard device for 
intraluminal pressure recordings [135 136].  
 
We also recorded simultaneously the transmural potential difference (PD) through the 
jejunal recording point at the end of the tube (1) and the middle recording point in the 
descending duodenum (4), using an infusion of isotonic saline (instead of water) as a 
flowing electrode. PD was measured between calomel half-cells and a common reference 
electrode connected to a subcutaneous infusion of saline. 
 
This mode of recording enabled us to measure PD and pressure at the same time and 
location. Intestinal motor activity and PD were recorded for three hours in the 
interdigestive state. The subjects were then given a standardized test meal (for details see 
paper III) and recordings were continued for another hour. 
 
 
Data processing 
 
The raw data were stored as ASCII files and were processed by specially designed 
software in Matlab code. A phase III of the MMC complex was identified by the 
computer software defined as 10-12 contractions/minute, duration of minimum 120 
seconds and distal propagation. Phase II was defined as the time window of 15 minutes 
before phase III and phase I as the interval of 15 minutes after the phase III complex. The 
data were also checked manually by a person unaware of the automatically generated 
results. 
 
The main recorded motor parameters were the number of phase III –s and the time 
duration of these complexes. The software had registered all contractions and 
consequently the contraction frequency was calculated both in fasting and fed state. The 
closely spaced side holes allowed us to recognize the propagation direction of the pressure 
waves [53]. 
 
Recorded secretory parameters: were those concerning the PD curve. Mean PD during 
fasting and fed conditions in phase I, II and III were calculated by the software. The 
maximum PD during phase III was also manually checked.  
 
The propagation velocity of the phase III complex was calculated by dividing the 
distance between the duodenal and jejunal recording points (in fact a constant) with the 
time interval needed for the end of the phase III to reach from the duodenal to the jejunal 
recording point. 
 
The length of the small intestinal segment with ongoing phase III activity the “motility 
length” was calculated as the product of [phase III propagation velocity] and [time 
duration of phase III], (cm/min * min = cm), between the mid duodenal (4) and proximal 
jejunal (1) recording channel. 
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The amount of chloride secretion during phase III was estimated as the following 
product: [mean phase III PD] *[phase III duration]*[phase III propagation velocity]* 
[number of phase III:s /3 hour recording period], (mV * min *cm/min *a digit = mV).  
 
Methodological comment: First, it was shown by Geall et al that PD between the 
peripheral venous blood and the gastrointestinal mucosa is the same as between the serosa 
and mucosa [137] Afterwards it was concluded by Wingate et al that the PD between the 
mucosal and serosal surface is the same as between the mucosa and a subcutaneous 
compartment [138]. Accordingly, an intravenous or a subcutaneous electrode shows the 
same electric potential as the serosal one. To sum up, the PD between the mucosal and 
serosal surface of the intestine can be measured indirectly by measuring the PD between 
the mucosa and a subcutaneous compartment in the forearm. 
 
 
 
3.8 Statistical methods 
 
Due to relatively low number of study participants and non-gaussian distribution of 
parameters we used nonparametric methods, Man-Whitney U test and Wilcoxon signed 
rank test. In order to evaluate the reproducibility of the 75SeHCAT test, the repeatability 
coefficient was used in diarrhoea patients, as described by Bland and Altman [139]. For 
further description see statistical methods in paper I. With a good concordance of this 
coefficient, 95% of the differences should to be less than two standard deviations (SD). 
 
The relationships between the 75SeHCAT values and other parameters were calculated 
using a logarithmic regression model based on the reasoning described by Sauter et al 
[140]. 
The kinetics of bile acids follows a one-compartment model. In a one-compartment model 
the synthesis of the bile acids is increased exponentially with the decrease of its half-life 
(or with the decrease of the 75SeHCAT retention values). This means that is appropriate to 
use exponential or logarithmic equation when relating the 75SeHCAT retention values to 
the bile acid synthesis (C4) or to symptoms (Number of stools). 
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4. RESULTS 
 
4.1 Diagnostic accuracy and reproducibility of the 75SeHCAT test  
(Paper I) 
 
In the retrospective study with chronic diarrhoea patients, 43 had performed the test twice. 
Four patients were excluded because of major intervention which could alter the outcome 
of the test, i.e. ileocaecal resection (2), cholecystectomy (1) and treatment for coeliac 
disease (1). 
 
In the prospective study with healthy controls 16 had performed to tests with a time 
interval of sixteen years. The body mass index (BMI) was registered at both occasions 
and increased significantly by 12% (from 23 ±3.1 kg/m2 to 25.7, ±4.6 kg/ m2, p<0.01).The 
reproducibility index is illustrated in Fig.4.  
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Figure 4. The reproducibility index of the 75SeHCAT test. 
 
Comments: The diagnostic consistency of the 75SeHCAT test is excellent in diarrhoea 
patients, only 1 patient of 39 is outside the limit of Mean + 2SD. In healthy controls there 
is a greater difference, 3 of 16 are outside the limit of Mean + 2SD. However, in healthy 
controls there was a significant decrease between the two test values. This could be a true 
physiological phenomenon linked to the increase in body mass index BMI, by 13%, from 
a median of 23.2 kg/m2, (21 - 24.6) to 26.2 kg/ m2, (22.5 – 27.8), p<0.01) during the 16 
years. 
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4.2 Correlation between symptoms, bile acid turnover rate 
 (75SeHCAT) and hepatic bile acid synthesis (C4)  
 (Paper I, II, IV) 
 
The average stool frequency per day during the week of the 75SeHCAT measurement was 
registered in almost all participants: healthy subjects (paper I), diarrhoea patients (paper 
II) and patients with collagenous colitis (paper IV). When the data from the three studies 
is added together the following correlations were found and presented in Fig. 5, Fig. 6 and 
Fig. 7. 
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Figure 5. 75SeHCAT test and stool frequency r = 0.5, p < 0.001, n = 52. logarithmic 
  regression.  
 
 
 
In the individual studies, the correlations were the following: 
 
• 75SeHCAT test and stool frequency (paper I): r = 0.321, p = 0.336, n = 11 
logarithmic regression. 
 
• 75SeHCAT test and stool frequency (paper II): r = 0.492, p < 0.001, n = 41 
logarithmic regression in the mixed diarrhoea population. 
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Figure 6. C4 and stool frequency r = -0.697, p < 0.001, n = 41 simple regression. 
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Figure 7. 75SeHCAT test and C4 r = 0.621, p < 0.001, n = 57 logarithmic regression. 
 
There was only minimal difference when the C4 values were corrected for plasma 
cholesterol. 75SeHCAT test and C4/cholesterol r = 0.624, p < 0.001, n = 53. 
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In paper IV, in the collagenous colitis group we registered the stool consistencies and 
other symptoms like pain, abdominal gas and bloating both before and during budesonide 
treatment. The correlation matrix before treatment is presented in the table. The statistical 
significance was calculated by Fischer’s test. A p value < 0.05 is marked with *, p<0.01 
with** and p<0.001 with ***. Data from sixteen patients were used to compute the 
correlation matrix, see Table 2. 
During budesonide treatment there were no significant correlations between the different 
parameters. 
 
 
Table 2. The correlation matrix between symptoms and 75SeHCAT test and C4. 
 
 75SeHCAT C4 Frequency Consistency Pain Bloating Gas 
75SeHCAT 1 -.52* -.57* .36 -.67** -0.145 0.61* 
C4 -.52* 1 .73*** -.52* .26 .14 -.22 
Frequency -.57* .73*** 1 -.51* .41 .89 -.14 
Consistency .36 -.52* -.51* 1 .064 .035 .11 
Pain -.67** .26 .41 .064 1 .49 -.31 
Bloating -.145 0.14 .89 .035 .494 1 .340 
Gas .61* -.21 -.14 .11 -.31 .34 1 
 
 
Comments: The plasma C4 measurements and the 75SeHCAT tests although strongly 
correlated they reflect different variables. In steady state condition C4 mirrors the hepatic 
synthesis which is an absolute value. The 75SeHCAT tests mirrors the fractional turnover 
rate, i.e. a fraction or percentage. In some diseases it is possible that a high 75SeHCAT 
tests corresponds to high C4 values – e.g. in celiac disease, where the bile acid pool is 
very large [26]. In this disease the C4 test, which mirrors the absolute amount of bile acids 
reaching to colon, might be more accurate.  
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4.3 Bile acid uptake capacity in isolated biopsies from the ileum  
(Paper II) 
 
The results are presented as median, (percentile 25 and 75). Patients with diarrhoea had a 
significantly higher uptake of taurocholate: 7.7 μmol/ g·min, (6.1 and 9.7), n=53, 
compared with the controls: 6.1 μmol/ g·min, (4.5 and 6.9), n=17 (p<0.01). Se Fig. 8. 
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Figure 8. Bile acid uptake capacity in all diarrhoea patients compared to   
  controls. 
 
The uptake among patients with abnormal 75SeHCAT values was significantly higher: 7.4 
μmol/ g·min, (7 and 8.9), n=18, than in the controls (p<0.01), see Fig. 9. 
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Figure 9. Bile acid uptake capacity in diarrhoea patients with bile acid    
  malabsorption compared to controls. 
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There was no significant difference between patients with abnormal 75SeHCAT test and 
those with diarrhoea and normal 75SeHCAT values: 8.5 μmol/ g·min, (6.1 and 10), n=23 
(p=0.44, ns)  
 
The correlation between bile acid uptake capacity and ASBT/Villin ratio based on 
ranking showed identical ranking with the exception of 2 values, Fig 10. 
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Figure 10. Correlation between the rankings of the two tests. 
 
 
There was a lack of correlation between bile acid uptake capacity and the following 
parameters: 
Gender: males n=22 and females n=31 (p=0.8) in the diarrhoea group, or in controls, 
males n=8, females n=9 p=0.85.  
Age: r=0.08, n=17, (p=0.77) in controls and r=0.15, n=53, p=0.3 in diarrhoea patients. 
75SeHCAT retention r=0.141, n=41, (p=0.39)  
Hepatic synthesis of bile acids measured by the (C4) values r=0.151, n=26 (p=0.47). 
 
 
 
4.4 Estimated chloride secretion in patients with bile acid 
 malabsorption compared to healthy controls 
 (Paper III) 
 
In the fasting or interdigestive state the total amount of chloride secreted in the 
simultaneously contracting segment was calculated from the product of segment length 
and mean PD, and by multiplying this value with the number of phase III periods per 3 
hour period (duration of experiment in fasting state). The estimated value for total 
chloride secretion (“interdigestive secretory index”) was higher in patients with bile acid 
malabsorption [510.7 mV*cm, (357.3-823.8), n=9] vs. controls [307.8 mV*cm, (180.2-
374.9), n=10], (p<0.01), see Fig. 11. 
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In the fed state there were no significant differences in the magnitude of the motor or 
secretory response to feeding between controls and BAM patients. The time course and 
magnitude of the PD response to feeding was in fact almost identical in controls and 
BAM patients, and this was true in both duodenum and jejunum.  
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Figure 11. The estimated chloride secretion in patients with bile acid    
  malabsorption compared to healthy subjects in the fasting state. 
 
 
 
4.5 Correlation between estimated chloride secretion and the 
 75SEHCAT test  
 (Paper III) 
 
The amount of chloride secretion during phase III was estimated as the following 
product: [mean phase III PD] *[phase III duration]*[phase III propagation velocity]* 
[number of phase III:s /3 hour recording period], (mV * min *cm/min *a digit = mV).  
This estimation could be done in nine patients and the graph is presented in Fig.12 on the 
next page. 
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Figure 12. The correlation between the estimated chloride secretion and the   
  75SeHCAT test in patients with bile acid malabsorption. 
 
 
 
4.6 Budesonide treatment 
 
 
4.6.1. The effect on bile acid turnover rate (75SeHCAT test) 
 
The 75SeHCAT test was performed in 25 patients before treatment and after 8 weeks of 
budesonide therapy. Six patients (24%) had an abnormal value initially. The seventh day 
retention values increased from 18% (11% and 28%) to 35% (19% and 46%), (p<0.0001). 
The 29 healthy controls 75SeHCAT values were 38% (29% and 48%). Thus, the 
difference between the collagenous colitis group and healthy controls (p<0.0001) 
disappeared during the treatment, (p=0.26), see Fig. 13. 
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Figure 13. The 75SeHCAT test in collagenous colitis patients before and during   
  treatment compared to healthy control subjects. 
 36
 
 
 
4.6.2. The effect on bile acid synthesis (C4) 
 
The plasma C4 concentrations were analyzed in 19 of the patients before and during 
budesonide treatment, see Fig .14. 
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Figure 14. The estimated bile acid synthesis before and during budesonide   
  treatment in patients with collagenous colitis. 
 
 
The nine patients with initial plasma C4 concentrations over 20 ng/ml showed a 
significant drop of their C4 values during treatment, from 36 ng/ml (24 ng/ml and 60 
ng/ml) to 23 ng/ml (10 ng/ml and 35 ng/ml)(p=0.04). Their 75SeHCAT retention values 
increased from 12% (3% and 18%) to 21% (11% and 35%), (p=0.03). 
 
In the whole group of investigated patients the C4 values decreased from 19 ng/ml (9 
ng/ml and 33 ng/ml) to 13 ng/ml (10 ng/ml and 23 ng/ml), (p = 0.23 ns). Nine patients had 
higher and 10 had lower levels during the two measurements.  
The C4 values decreased in 5 of the 6 patients with bile acid malabsorption but the small 
number didn’t allow to reach statistical significance. 
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4.6.3. The effect on symptoms 
 
The stool frequencies decreased from 4.15/day (3.5/day and 5.4/day) to 1.8/day (1.1/day 
and 2.3/day), (p < 0.0001), n = 21.  
The scores for stool consistency improved from 1.7 (1.15 and 2) to 2.7 (2 and 2.9) (p < 
0.001), n = 20.  
The scores for pain improved from 1.3 (0.93 and 2) to 0.2 (0 and 0.6) (p < 0.01), n = 18. 
The abdominal distension (bloating) score improved from 1 (0 and 1.5) to 0.15 (0 and 1) 
(p <0.01), n=13. 
The scores for flatulence ameliorated from 1.3 (0.7 and 1.7) to 0.3 (0 and 1) (p<0.05).  
 
The improvement of the symptoms did not differ between the patients with initially high 
C4 values and those with C4 < 20 ng/ml. In the group with initially higher bile acid 
synthesis, with C4 values >20 ng/ml there was a tendency toward more frequent stools, 
4.7/day (4.1/day and 7.5/day) compared to the group with C4 values <20 ng/ml, 4/day 
(3/day and 4.3/day), (p=0.06) Otherwise, the symptom scores did not differ regarding 
consistency, pain, abdominal distension or flatulence. 
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5. GENERAL DISCUSSION – POSSIBLE CAUSES OF 
IDIOPATHIC BILE ACID MALABSORPTION 
 
 
5.1 Short summary 
 
The present thesis deals with intestinal absorption of bile acids with special reference to 
the mechanisms behind idiopathic bile acid malabsorption. In paper I we found that the 
turnover rate of bile acids is stable during a long period of time, both in diarrhoea and in 
health. Despite of the somewhat lower 75SeHCAT retention values after sixteen years in 
healthy subjects, this decrease is of less magnitude to cause bile acid malabsorption. We 
also tested the relationship between age and the values of the 75SeHCAT test in paper I, II 
and III and we can conclude that ageing is not correlated to this condition. 
 
The BMI (body mass index) of the healthy subjects increased significantly during the 
study period at the same time when 75SeHCAT values decreased. If the relationship 
between these two variables is real the accelerated turnover rate of bile acids reflected by 
the decreased 75SeHCAT values may thus be a consequence of a westernized lifestyle. 
 
The results of paper II suggest that this condition is not caused by an impaired bile acid 
uptake system at the level of the terminal ileum – the uptake capacity was increased in 
diarrhoea patients irrespectively of the 75SeHCAT test values.  
 
In paper III we could show an inverse correlation between the 75SeHCAT retention 
values and the estimated small bowel secretion, i.e. with increasing level of bile acid 
malabsorption there is a parallel increase in fluid secretion in the small bowel. 
 
There was a significant inverse correlation between the 75SeHCAT test and hepatic bile 
acid synthesis both in health and in diarrhoea (paper I and II). To our knowledge this is 
the first measurement in healthy subjects and also in diarrhoea where all the patients had 
macroscopically normal terminal ileum and none of them had bowel resection. 
 
Concerning the mechanism of action of budesonide in collagenous colitis we found that 
the treatment significantly increased 75SeHCAT values and improved the symptom scores 
(paper IV). It also decreased hepatic bile acid synthesis in patients with initially high 
synthesis rate, as determined from the serum marker C4. These results suggest that the 
effect of budesonide in collagenous colitis may partly be linked to a reduced bile acid load 
on the colon. 
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5.2 Impaired ileal bile acid uptake system 
 
A key finding of the thesis is that bile acid malabsorption diagnosed by the 75SeHCAT 
test is characterized by normal or high ileal uptake capacity. This is in line with the study 
by van Tilburg et al, which also showed an increased uptake using brush border 
membrane vesicles prepared from terminal ileal biopsy specimens from 10 patients who 
fulfilled the criteria of idiopathic bile acid diarrhoea [100]. Furthermore, in a subsequent 
study they demonstrated that these patients have an expanded bile acid pool [101]. 
 
In two studies of Montagnini et al no functional ASBT mutations were identified in 13 
patients with bile acid malabsorption or in a family with bile acid malabsorption in three 
consecutive generations[99 141]. Furthermore, there were no mutations or polymorphisms 
in the genes for several of the nuclear receptors known to be important for ASBT 
expression: the farnesoid X receptor (FXR) and peroxisome proliferator activated receptor 
alpha (PPAR alpha). 
 
Interestingly, in a recent study with a mouse model of postinfective gut dysfunction the 
ileal bile acid absorption was decreased, despite of an increased ASBT expression [142]. 
The authors postulated that the transport function of the protein may have been inhibited 
after infection. However, the results of paper II show an increased bile acid uptake 
capacity of the ileal biopsies and are contradicting the idea of diminished transport 
function. An alternative explanation may be that the excretion of bile acids through the 
basolateral membrane is altered. 
 
We did not find any reduced bile acid uptake capacity of the few patients with 
collagenous colitis investigated in paper II. Interestingly, these patients had normal 
75SeHCAT values. However, in paper IV, the 75SeHCAT values were abnormal in almost 
in a quarter of the patients with collagenous colitis initially and normalized during 
budesonide treatment.  
 
 
5.3 Increased bile acid pool 
 
The maintenance of the pool is mainly achieved by de novo synthesis in the hepatocyte 
and by active absorption in the ileum. The hepatic enzyme system is highly inducible and 
in extreme cases such as biliary fistulas the daily synthesis of bile acids can increase up to 
20-fold [23]. We also found a wide range in the plasma concentrations of C4 pointing to 
great variation in the hepatic synthesis rate of bile acids. 
 
The transport proteins of the ileal system, where the most studied is ASBT, are inducible 
too but probably with a lower magnitude i.e. only1-2 fold. Jung et al found in healthy 
controls an increase of the ASBT protein expression 1,34 fold after 21 days of budesonide 
treatment [75]. The relationship between ASBT protein concentration in the gut and its 
effect on bile acid uptake it is not known today. 
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The bile acid pool size was determined in previous studies in healthy subjects with a 
median value of 2.7 g (25th to 75th percentile 2.5 to 3.1 g) [143]. The fecal bile acid losses 
in healthy subjects can vary between 0.08-0.84 g/day with average of 0.4 g/day [144]. If we 
assume that a healthy subject reabsorbs the amount of bile acids equal to the pool size 
minus daily losses, the reabsorbed amount is approximately 2.7g-0.4g = 2.3g per day. The 
reabsorbtion rate is 2.3g/2.7g = 0.85. In seven days this calculation should be repeated six 
more times, with each day leaving 0.85 of the amount of the previous days, thus it 
remains (0.85) 6 = 0.377 or 37.7% of the original pool. This estimate is in line with the 
median value of 38 % of the 75SeHCAT at day 7 in a former investigation [17].  
 
We found that bile acid malabsorption patients have an increased uptake capacity, 
approximately 1.2 times compared to patients with normal bowel habits. If we assume 
that the daily amount of bile acids they absorb is 2.3g*1.2 = 2.76 g/day and at day 7 the 
median 75SeHCAT is 3.5 % or (0.035), than their first day retention will be 6 035.0 = 
0.57. This means that approximately 43 % of their bile acid pool is lost every day. If 
patients with bile acid malabsorption can absorb 2.76 g/ day but day loose each day 43% 
of the pool than their total bile acid pool should be 2.76 g*100/57 = 4.84 g, almost double 
sized compared to normal subjects. This assumption is in line with the finding of van 
Tilburg et al in 8 patients with BAM where the average pool size was 7 mmol, compared 
to 3,7 mmol in healthy subjects [101].  
 
If the high uptake in ileal biopsies mirrors an increased total in vivo re-absorption of bile 
acids from the small intestine this should normally lead to a suppression of the hepatic 
bile acid synthesis. The increased synthesis in bile acid malabsorption therefore suggests 
that the feedback system may be hampered. The high synthesis will lead to higher 
concentrations of bile acids within the gut and subsequently may overload the saturable 
active uptake system.  
 
In a study by Sadik et al patients with bile acid malabsorption had an increased body mass 
index [61]. High fat intake increases the synthesis rate of bile acids in animal models [145].  
 
A low-fat diet was found to decrease the excretion of bile acids, both in ileostomy patients 
as well as in patients with bile acid diarrhoea caused by pelvic irradiation for malignant 
gynaecologic tumours [116 146]. Seemingly, there is a connection between high fat intake 
and bile acid excretion which in turn may cause with time an increased bile acid pool. 
 
 41
 
5.4 Shorter ileal segment with active bile acid uptake 
 
The length of the segment with ASBT protein expression is not known in patients with 
bile acid malabsorption. If the segment with active absorption is shorter than normal the 
total absorption of bile acids may be decreased although the active uptake in the very 
distal part of the small bowel is up-regulated. 
 
 
5.5 Faster motility 
 
If the luminal bile acids “bypass” the reabsorbing epithelium due to reduced contact time 
(e.g. faster motility of the small intestine), this might explain a seemingly impaired 
absorption despite normal capacity. A study by Sadik et al shows that patients with bile 
acid malabsorption type 2 have a more rapid small bowel transit measured with 
radioopaque markers compared with healthy controls [61]. 
  
Since there is a hepatic feedback system that increases bile acid synthesis when bile acid 
reabsorption is reduced, the bile acid load on the intestine will increase further which will 
result in increased secretion and motor activity etc, i.e. a classical positive feedback 
circuit [30]. It is theoretically possible that the beneficial effect of cholestyramine in these 
patients is to break this positive feedback circuit. If the hypothesis is correct, it might also 
explain the beneficial effect of loperamide, since opiates have an inhibitory effect on 
enteric secretomotor neurons, and also reduce intestinal motor activity [147].  
 
 
5.6 Increased small bowel secretion 
 
In the duodenum, phase III is preceded by partial gall bladder emptying, i.e. the mucosa 
of the receiving segment contains quite high concentrations of bile acids which has been 
proposed to contribute to the maintenance of motor activity [148]. During the MMC cycle 
the motor activity is coupled to the secretory activity, e.g. net fluid secretion occurs 
mainly during the late part of the MMC cycle when there is high motor activity and a 
more lumen negative PD [149]. 
 
We found an increased jejunal PD in patients with bile acid malabsorption compared to 
healthy controls in paper III. Furthermore, there was an inverse correlation between the 
75SeHCAT retention values and the estimated chloride secretion in bile acid 
malabsorption, e.g. with increasing level of bile acid malabsorption there was a parallel 
increase in chloride secretion. This finding might be in line with the assumption of 
increased bile acid pool in patients with bile acid malabsorption type II. 
 
The present data suggest that in patients with bile acid malabsorption as diagnosed by a 
pathological 75SeHCAT test, the small intestine may generate an increased fluid load on 
the colon. Depending on contact time in the colon, this fluid will be partially reabsorbed. 
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Colonic transit time is reduced in bile acid malabsorption [61] and bile acids may per se 
increase colonic motility [150]. Even a modest increase in the fluid load from the small 
intestine may therefore be symptom generating in these patients. Interestingly, bile acids 
are also able to generate propulsive motility in the ileum, and administration of bile acids 
to patients with “irritable colon” was shown to increase ileal PD (i.e. probably generate 
secretion) [63]. 
 
The current findings may account for the puzzling observation of paper II, that despite 
normal or increased ileal bile acid reuptake capacity, patients with bile acid malabsorption 
lose bile acids via the stools. However, if there is an increased fluid secretion in the small 
intestine, then luminal bile acids may bypass the reabsorbing epithelium due to “dilution 
effect”. This dilution effect was tested previously in a study by Fellous et al, when the 
administration of an osmotic laxative resulted in lower 75SeHCAT test values (22%) 
compared to untreated subjects, who had 44% retention after seven days [151].  
 
Surprisingly, the PD response to feeding was almost identical in controls and BAM 
patients. This finding should be interpreted with some caution, since the test meal will 
change the chemical environment in the lumen which may per se induce electrochemical 
gradients that may mask small group differences. 
 
The results of paper III suggest that patients with diarrhoea and reduced ability to retain 
bile acids produce elevated amounts of chloride in the proximal small intestine in 
association with phase III of the migrating motor complex. Increased ileal fluid load, 
possibly in combination with a reduced ileal transit time, might hydrodynamically reduce 
bile acid reuptake despite a normal active bile acid absorption capacity. 
 
 
5.7 The effect of budesonide in collagenous colitis 
 
Probably, the pathophysiology of bile acid malabsorption is different in idiopathic bile 
acid malabsorption (type II) compared to type III. 
 
Patients with collagenous colitis often have bile acid malabsorption and they also respond 
to resin treatment [17]. When bile acid malabsorption is present, the condition can be 
classified as type III. In a recent study, TNF alpha could not be detected in the faecal 
samples of these patients [152], in contrast to patients with Crohn’s disease [153]. 
Inflammatory cytokines repress ASBT protein expression in Caco-2 cell cultures and in 
animal models [71] and ASBT is also down-regulated in Crohn’s disease [154]. 
However, in contrast to Crohn’s disease, in collagenous colitis there is no inflammation in 
the terminal ileum [17]. 
 
In collagenous colitis there is a colonic inflammation, and probably an altered reactivity 
of the colonic epithelium to bile acids. 
In vitro experiments have shown that the predominant diarrhoea mechanism in 
collagenous colitis is a reduction of the net Na+ and Cl- absorption accompanied by 
electrogenic chloride secretion. There is also a down-regulation of tight junctions which 
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contributes to the diarrhoea by leak flux mechanisms [155]. The effects of bile acids on the 
colonic mucosa resemble in part these mechanisms. Thus, there are data showing that bile 
acids induce diarrhoea by reduced absorption and by increased permeability which is 
suggested to be partly due to influence on the tight junctions [90]. 
 
Budesonide has well established anti-inflammatory features, most studied in Crohn’s 
disease [114]. Direct anti-inflammatory influences on the colonic mucosa may also 
contribute to the benefit of budesonide in collagenous colitis. 
 
Budesonide treatment significantly increased the 75SeHCAT values and improved the 
symptom scores. It also decreased hepatic bile acid synthesis in patients with initially high 
synthesis rate, as determined from the serum marker C4. The results suggest that 
budesonide increases the intestinal active uptake of bile acids indicating that its clinical 
effect in collagenous colitis may partly be linked to a reduced bile acid load on the colon.  
 
 
 
5.8 Conclusions- Bile acid induced diarrhoea 
 
The findings of this thesis suggest that the term “idiopathic bile acid malabsorption” is not 
appropriate, hence there is no reduced absorption capacity in the terminal ileum of these 
patients. The values of an abnormal 75SeHCAT test are inversely correlated to chloride 
secretion in the proximal small bowel indicating that bile acids play a role in the 
pathophysiology of diarrhoea. A more suitable term for this disease entity would be bile 
acid induced diarrhoea.  
 
Further studies are needed to investigate the volume of the bile acid pool in bile acid 
induced diarrhoea and its connection to increased body mass index and westernized 
lifestyle. 
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